Trial Profile
Phase II Study of Hu3F8, Irinotecan/Temozolomide and Sargramostim (HITS) Chemoimmunotherapy for High-Risk Neuroblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2023
Price :
$35
*
At a glance
- Drugs Naxitamab (Primary) ; Granulocyte macrophage colony stimulating factor; Irinotecan; Sargramostim; Temozolomide; Temozolomide
- Indications Neuroblastoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms HITS
- 16 Oct 2023 According to a Y-mAbs Therapeutics media release, data from this study were published in the journal Cancers.
- 16 Oct 2023 Results published in an Y-mAbs Therapeutics Media Release.
- 16 Oct 2023 According to a Y-mAbs Therapeutics media release, Dr. Jaume Mora is the principal investigator of this study.